Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Study to Assess the Renoprotective Effects of the SGLT2 Inhibitor Dapagliflozin in Non-Diabetic Patients With Proteinuria: a Randomized Double Blind 6-Weeks Cross-Over Trial

Next Previous
Trial Profile

A Study to Assess the Renoprotective Effects of the SGLT2 Inhibitor Dapagliflozin in Non-Diabetic Patients With Proteinuria: a Randomized Double Blind 6-Weeks Cross-Over Trial

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 19 Jun 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dapagliflozin (Primary)
  • Indications Proteinuria
  • Focus Therapeutic Use
  • Acronyms DIAMOND

Most Recent Events

  • 01 Aug 2021 Results of post-hoc exploratory analysis of three randomized studies (DELIGHT (NCT02547935), IMPROVE (Netherlands Trial Register NTR4439) and DIAMOND (NCT03190694)) published in the Diabetes, Obesity and Metabolism.
  • 15 Feb 2021 Primary endpoint has not been met. (Change in 24-hr proteinuria with dapagliflozin for six weeks relative to placebo in patients with non-diabetic kidney disease and proteinuria 500 mg/day on stable angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker treatment.), as per published in the Clinical Pharmacokinetics
  • 15 Feb 2021 Results (n=48) assessing pharmacokinetic profile of dapagliflozin in patients with chronic kidney disease without type 2 diabetes, published in the Clinical Pharmacokinetics

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top